| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/21/2001 | CN1284873A Water-base liquid preparation |
| 02/21/2001 | CN1284869A Treatment of chronic inflammatory disorders of gastrointestinal tract |
| 02/21/2001 | CN1284867A Process for manufacturing bite-dispersion tablets |
| 02/21/2001 | CN1284866A Oral pharmaceutical extended release dosage form |
| 02/21/2001 | CN1284864A Novel formulation for use in pain management |
| 02/21/2001 | CN1284863A Topical compositions for NSAI drug delivery |
| 02/21/2001 | CN1284862A Topical compositions for prostaglandin E1 delivery |
| 02/21/2001 | CN1284861A Novel pharmaceutical compositions of uridine triphosphate |
| 02/21/2001 | CN1284860A Microparticles and their therapeutic or diagnostic use |
| 02/21/2001 | CN1284330A Medicinal aerosol preparation, its preparing method and release |
| 02/21/2001 | CN1062161C Process for preparation of stable fleabane extract injection |
| 02/21/2001 | CN1062130C Medical liposome ointment |
| 02/21/2001 | CN1062129C Medicine matrix and its use |
| 02/20/2001 | US6191301 Protecting the human epidermis or human hair from ultraviolet radiation, both the a and b rays, specifically in the range from 320 to 400 nm; protect other ingredients from decomposition or breakdown by uv radiation; |
| 02/20/2001 | US6191290 An anticarcinogenic compound comprising a taxane derivative conjugated to a receptor ligand peptide; conjugating covalently a receptor ligand peptide to a solubilizing linker and ligating the peptide-conjugated linkers to |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/20/2001 | US6191137 Pharmaceutical composition for oral administration |
| 02/20/2001 | US6191105 Insulin free compositions with insulin-methyl(ethylene glycol)-o-hexanoic acid conjugate and composition with water in oil microemulsion |
| 02/20/2001 | US6190894 Method and compositions for disrupting the epithelial barrier function |
| 02/20/2001 | US6190701 For delivering vaccines and drugs |
| 02/20/2001 | US6190698 Stability; discoloration inhibition; used as antipsychotic agent |
| 02/20/2001 | US6190695 Preventing or treating various bone diseases (e.g., osteoporosis); oral absorbability and stability |
| 02/20/2001 | US6190694 Rendering chitosan into powder; adding chitosan powder, powder comprising organic acid and salt thereof, and an emulsifier to an oil or fat; stirring mixture so as to suspend powders, obtain a gel-like stock and gelatin solution for encapsulation |
| 02/20/2001 | US6190686 Water dispersible compositions containing natural hydrophobic pigment, method of preparing same and their use |
| 02/20/2001 | US6190685 Antioxidizing composition for scavenging free radicals, pharmaceutical composition comprising the same, and process for preparing the same |
| 02/20/2001 | US6190668 Providing cell mass of moraxella catarrhalis strain grown under iron-starved conditions to stimulate transferrin receptor protein expression; selectively extracting aqueous soluble proteins; separation; solubilizing; purification mass |
| 02/20/2001 | US6190650 For prophylaxis and therapy of viral diseases in humans and animals |
| 02/20/2001 | US6190640 Administering indium radiolabelled humanized monoclonal antibody or a in radiolabelled binding fragment of a humanized monoclonal antibody which binds to antigen a33 which is presented on surfaces of cells of cancer carcinoma |
| 02/20/2001 | CA2316329A1 Additive for improving the water resistance of cosmetic or dermatological formulations |
| 02/20/2001 | CA2195005C Multifunctional cross-linking reagents for hemoglobin, and cross-linked hemoglobin conjugates |
| 02/20/2001 | CA2083404C Therapeutically effective topical application of st1435 |
| 02/20/2001 | CA2014569C Orally administered pharmaceutical composition for use in gastrointestinal washes, in particular for diagnostic use, or as cathartic laxative |
| 02/15/2001 | WO2001011041A1 MONOMERIC PROTEIN OF THE TGF-β FAMILY |
| 02/15/2001 | WO2001010913A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 02/15/2001 | WO2001010741A1 Valve with a two-component seal |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010466A1 Stable medicinal compositions for oral use |
| 02/15/2001 | WO2001010465A1 Moxifloxacin formulation containing common salt |
| 02/15/2001 | WO2001010464A1 Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same |
| 02/15/2001 | WO2001010463A1 Pastes with the sustained release of osteogenesis promoter |
| 02/15/2001 | WO2001010454A2 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 02/15/2001 | WO2001010450A1 Targeted thrombolytic agents |
| 02/15/2001 | WO2001010447A1 Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration |
| 02/15/2001 | WO2001010446A2 Formulations for parenteral use of estramustine phosphate and albumin |
| 02/15/2001 | WO2001010430A2 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 02/15/2001 | WO2001010421A1 Drug releasing biodegradable fiber implant |
| 02/15/2001 | WO2001010419A1 Hydrodynamically balancing oral drug delivery system |
| 02/15/2001 | WO2001010418A1 Means for creating a mass having structural integrity |
| 02/15/2001 | WO2001010415A1 A binder for pharmaceutical compositions |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010410A1 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof |
| 02/15/2001 | WO2001010409A1 Aqueous nasal formulation |
| 02/15/2001 | WO2001010408A2 Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| 02/15/2001 | WO2001010407A1 Intravaginal clindamycin ovule composition |
| 02/15/2001 | WO2001010405A1 Hydrodynamically balanced oral drug delivery system |
| 02/15/2001 | WO2001010378A2 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/15/2001 | WO2001010344A1 Nitric oxide releasing medical devices |
| 02/15/2001 | WO2000069900A3 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/15/2001 | WO2000066709A3 Zymogen activation system |
| 02/15/2001 | WO2000064946A3 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057852A3 Methods and compositions for treating solid tumors |
| 02/15/2001 | WO2000056866A3 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 02/15/2001 | WO2000053167A3 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 02/15/2001 | WO1999066902A8 Injectable pharmaceutical formulations of partricin derivatives |
| 02/15/2001 | DE19936997A1 Verfahren zur Nutzung von Dendrimeren als Multiplikatoren zur Verabreichung von Photosensibilisatoren Procedures for the use of dendrimers as multipliers for administration of photosensitizers |
| 02/15/2001 | DE19908766C2 Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien Use of synthetic Vpr peptides of human immunodeficiency virus type 1 (HIV-1) for the development of therapeutic and diagnostic reagents |
| 02/15/2001 | CA2381846A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 02/15/2001 | CA2380312A1 Formulations for parenteral use of estramustine phosphate and albumin |
| 02/15/2001 | CA2378591A1 Edible holographic products, particularly pharmaceuticals and methods and apparatus for producing same |
| 02/15/2001 | CA2378578A1 Means for creating a mass having structural integrity |
| 02/15/2001 | CA2378572A1 Intravaginal clindamycin ovule composition |
| 02/15/2001 | CA2378486A1 Osteogenesis promoter sustained-release paste |
| 02/15/2001 | CA2378468A1 Hydrodynamically balancing oral drug delivery system |
| 02/15/2001 | CA2378401A1 Implantable active ingredient depot |
| 02/15/2001 | CA2378267A1 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof |
| 02/15/2001 | CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
| 02/15/2001 | CA2348959A1 Methods of cytoprotection using an enantiomer of estrogen of ischemic damage |
| 02/15/2001 | CA2346291A1 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-.alpha.-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 02/15/2001 | CA2346063A1 Composition and methods for treatment of hiv infection |
| 02/14/2001 | EP1076066A1 Peptides for lowering blood glucose levels |
| 02/14/2001 | EP1075839A1 Plasma expander, blood diluent and cryoprotector produced using amylopectin-potato starch |
| 02/14/2001 | EP1075837A2 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/14/2001 | EP1075511A1 Size enhanced fibrinolytic enzymes |
| 02/14/2001 | EP1075496A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis |
| 02/14/2001 | EP1075461A2 Perfluorinated esters of alkanoyl l-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 02/14/2001 | EP1075287A1 Positron emission tomography using gallium-68 chelates |
| 02/14/2001 | EP1075282A1 Peg-lhrh analog conjugates |
| 02/14/2001 | EP1075281A2 Polyol-ifn-beta conjugates |
| 02/14/2001 | EP1075280A2 Hemoglobine-haptoglobin complexes for targeted durg delivery |
| 02/14/2001 | EP1075279A2 Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells |
| 02/14/2001 | EP1075276A2 Adjuvant composition and methods for its use |
| 02/14/2001 | CN1284086A Conjugates useful in treatment of prostate cancer |
| 02/14/2001 | CN1283997A Keratinocyte growth factor-2 formulations |
| 02/14/2001 | CN1283993A Method for producing solid dosing forms |
| 02/14/2001 | CN1283990A Long cating injectable formulations contg. hydrogenated castor oil |
| 02/14/2001 | CN1283989A Micropartical inhalation formulations |
| 02/14/2001 | CN1283643A Precursor of polyglycol carried taxusol or polyene taxusol |
| 02/14/2001 | CN1061843C Film for whitening teeth |